Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Selenium Methionine
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Cancer Trials New Zealand | Counties Manukau Health | Waikato Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Optimal Selenium for Bowel Polyps (OSCAR)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2021
Lead Product(s) : Selenium Methionine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Cancer Trials New Zealand | Counties Manukau Health | Waikato Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selenium Methionine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
SLM + Axitinib for Clear Cell RCC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2015
Lead Product(s) : Selenium Methionine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selenium Methionine
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : IBSA Institut Biochimique
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Semet (80 and 160 mcg) Versus Placebo in Euthyroid Patients With AIT
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2014
Lead Product(s) : Selenium Methionine
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : IBSA Institut Biochimique
Deal Size : Inapplicable
Deal Type : Inapplicable